Reflections on the Pivotal Lung Cancer Data of 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Funding from Daiichi Sankyo/Content Independently Developed by OncLive


EP. 1: Reviewing the Year 2021 in Lung Cancer Treatment

December 22nd 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

EP. 2: Shaping the Use of Immunotherapy in the Localized Lung Cancer Setting

January 7th 2022

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year. This episode is a review of the clinical advancements in lung cancer treatment throughout 2021. Funding from Daiichi Sankyo/Content Independently Developed by OncLive

EP. 3: How Has Immunotherapy Evolved in the Advanced NSCLC Setting?

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, highlight new therapeutic advances in the advanced setting of non–small cell lung cancer unveiled throughout 2021.

EP. 4: Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

EP. 5: Closing Out With KRAS and HER2 Advances in NSCLC

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD; conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.